Molecular aspects of tumour hypoxia

Molecular Oncology

Volumn 2, Issue 1, 2008, Pages 41-53

  Rademakers, Saskia E ^a   Span, Paul N ^a   Kaanders, Johannes H A M ^a   Sweep, Fred C G J ^a   van der Kogel, Albert J ^a   Bussink, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HIF 1; Hypoxic markers; Molecular response; Tumour hypoxia; Unfolded protein response, UPR

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 NITROIMIDAZOLE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CARBOGEN; CARBONATE DEHYDRATASE IX; CARBOPLATIN; CELL MARKER; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; COPPER 64; FLUORINE 18; FLUOROURACIL; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HYPOXIA INDUCIBLE FACTOR 1; INDISULAM; INITIATION FACTOR 2ALPHA; MISONIDAZOLE; NICOTINAMIDE; NIMORAZOLE; OSTEOPONTIN; PACLITAXEL; PIMONIDAZOLE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TIRAPAZAMINE; UNINDEXED DRUG; UROKINASE; UROKINASE RECEPTOR; VASCULAR TARGETING AGENT; VASCULOTROPIN;

CLINICAL TRIAL; DISEASE MARKER; HUMAN; HYPOXIA; LUNG NON SMALL CELL CANCER; MICROENVIRONMENT; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POLAROGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FOLDING; PROTEIN FUNCTION; RADIOSENSITIVITY; REVIEW; SOLID TUMOR;

EID: 43649107785     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2008.03.006     Document Type: Review

References (102)

1. R. Airley J. Loncaster S. Davidson M. Bromley S. Roberts A. Patterson R. Hunter I. Stratford C. West Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix Clin. Cancer Res. 7 2001 928 934
2. R.E. Airley J. Loncaster J.A. Raleigh A.L. Harris S.E. Davidson R.D. Hunter C.M. West I.J. Stratford GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding Int. J. Cancer 104 2003 85 91
3. S. Baer L. Casaubon M.R. Schwartz A. Marcogliese M. Younes Glut3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival The Laryngoscope 112 2002 393 396
4. K. Bajou V. Masson R.D. Gerard P.M. Schmitt V. Albert M. Praus L.R. Lund T.L. Frandsen N. Brunner K. Dano The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies J. Cell Biol. 152 2001 777 784
5. N.J. Beasley R. Leek M. Alam H. Turley G.J. Cox K. Gatter P. Millard S. Fuggle A.L. Harris Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients Cancer Res. 62 2002 2493 2497
6. K.L. Bennewith R.E. Durand Quantifying transient hypoxia in human tumor xenografts by flow cytometry Cancer Res. 64 2004 6183 6189
7. K.L. Bennewith J.A. Raleigh R.E. Durand Orally administered pimonidazole to label hypoxic tumor cells Cancer Res. 62 2002 6827 6830
8. J. Blais J.C. Bell Novel therapeutic target: the PERKs of inhibiting the integrated stress response Cell Cycle 5 2006 2874 2877
9. D.M. Brizel S.P. Scully J.M. Harrelson L.J. Layfield J.M. Bean L.R. Prosnitz M.W. Dewhirst Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma Cancer Res. 56 1996 941 943
10. D.M. Brizel G.S. Sibley L.R. Prosnitz R.L. Scher M.W. Dewhirst Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck Int. J. Radiat. Oncol. Biol. Phys. 38 1997 285 289
11. L.F. Brown A. Papadopoulos-Sergiou B. Berse E.J. Manseau K. Tognazzi C.A. Perruzzi H.F. Dvorak D.R. Senger Osteopontin expression and distribution in human carcinomas Am. J. Pathol. 145 1994 610 623
12. J. Bussink J.H. Kaanders A.J. van-der-Kogel Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers Radiother. Oncol. 67 2003 3 15
13. J. Bussink A.J. van der Kogel J.H. Kaanders Acivation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer Lancet Oncol. 9 2008 288 296
14. A.F. Chambers S.M. Wilson N. Kerkvliet F.P. O'Malley J.F. Harris A.G. Casson Osteopontin expression in lung cancer Lung Cancer (Amsterdam, Netherlands) 15 1996 311 323
15. D. Coppola M. Szabo D. Boulware P. Muraca M. Alsarraj A.F. Chambers T.J. Yeatman Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies Clin. Cancer Res. 10 2004 184 190
16. K. Dass A. Ahmad A. Azmi S. Sarkar F. Sarkar Evolving role of uPA/uPAR system in human cancers Cancer Treat. Rev. 2007 10.1016/j.ctrv.2007.1010.1005
17. I.D. Davis G.A. Wiseman F.T. Lee D.N. Gansen W. Hopkins A.T. Papenfuss Z. Liu T.J. Moynihan G.A. Croghan A.A. Adjei A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma Cancer Immun. 7 2007 13
18. F. Dehdashti M.A. Mintun J.S. Lewis J. Bradley R. Govindan R. Laforest M.J. Welch B.A. Siegel In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM Eur. J. Nucl. Med. Mol. Imaging 30 2003 844 850
19. M.W. Dewhirst Concepts of oxygen transport at the microcirculatory level Semin. Radiat. Oncol. 8 1998 143 150
20. S. Dische Hyperbaric oxygen: the Medical Research Council trials and their clinical significance Br. J. Radiol. 51 1978 888 894
21. S.M. Evans K.L. Du A.A. Chalian R. Mick P.J. Zhang S.M. Hahn H. Quon R. Lustig G.S. Weinstein C.J. Koch Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome Int. J. Radiat. Oncol. Biol. Phys. 69 2007 1024 1031
22. N. Ferrara H.P. Gerber J. LeCouter The biology of VEGF and its receptors Nat. Med. 9 2003 669 676
23. T. Fillies R. Werkmeister P.J. van-Diest B. Brandt U. Joos H. Buerger HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor BMC Cancer 5 2005 84
24. T. Fink A. Kazlauskas L. Poellinger P. Ebbesen V. Zachar Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1 Blood 99 2002 2077 2083
25. T.A. Fong L.K. Shawver L. Sun C. Tang H. App T.J. Powell Y.H. Kim R. Schreck X. Wang W. Risau SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types Cancer Res. 59 1999 99 106
26. R.A. Gatenby H.B. Kessler J.S. Rosenblum L.R. Coia P.J. Moldofsky W.H. Hartz G.J. Broder Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 14 1988 831 838
27. K. Grabmaier M.C. A-de-Weijert G.W. Verhaegh J.A. Schalken E. Oosterwijk Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma Oncogene 23 2004 5624 5631
28. C. Grau J. Overgaard Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ Cancer Chemother. Pharm. 30 1992 277 280
29. L. Gray A.D. Conger M. Ebert S. Hornsey O.C.A. Scott The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy Br. J. Radiol. 28 1953 638 648
30. E.O. Hanrahan J.V. Heymach Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer Clin. Cancer Res. 13 2007 4617 4622
31. L. Harris H. Fritsche R. Mennel L. Norton P. Ravdin S. Taube M.R. Somerfield D.F. Hayes R.C. Bast Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J. Clin. Oncol. 25 2007 5287 5312 Official Journal of the American Society of Clinical Oncology
32. M. Hockel K. Schlenger B. Aral M. Mitze U. Schaffer P. Vaupel Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res. 56 1996 4509 4515
33. M. Hockel K. Schlenger S. Hockel P. Vaupel Hypoxic cervical cancers with low apoptotic index are highly aggressive Cancer Res. 59 1999 4525 4528
34. M. Hockel P. Vaupel Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects J. Natl. Cancer Inst. 93 2001 266 276
35. I.J. Hoogsteen H.A.M. Marres K.I.E.M. Wijffels P.F.J.W. Rijken J.P.W. Peters F.J. van den Hoogen E. Oosterwijk A.J. van der Kogel J.H.A.M. Kaanders Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma Clin. Cancer Res. 11 2005 97 106
36. M.R. Horsman D.W. Siemann Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies Cancer Res. 66 2006 11,520 11,539
37. M. Hu K. Polyak Microenvironmental regulation of cancer development Curr. Opin. Genet. Dev. 2008 10.1016/j.gde.2007.12.006
38. S. Ivanov S.Y. Liao A. Ivanova A. Danilkovitch-Miagkova N. Tarasova G. Weirich M.J. Merrill M.A. Proescholdt E.H. Oldfield J. Lee Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer Am. J. Pathol. 158 2001 905 919
39. R.A. Jonathan K.I. Wijffels W. Peeters P.C. de Wilde H.A. Marres M.A. Merkx E. Oosterwijk A.J. van der Kogel J.H. Kaanders The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON Radiother. Oncol. 79 2006 288 297
40. J.H. Kaanders J. Bussink A.J. van der Kogel ARCON: a novel biology-based approach in radiotherapy Lancet Oncol. 3 2002 728 737
41. J.H. Kaanders L.A. Pop H.A. Marres I. Bruaset F.J. van den Hoogen M.A. Merkx A.J. van der Kogel ARCON: experience in 215 patients with advanced head-and-neck cancer Int. J. Radiat. Oncol. Biol. Phys. 52 2002 769 778
42. J.H. Kaanders K.I. Wijffels H.A. Marres A.S. Ljungkvist L.A. Pop F.J. van den Hoogen P.C. de Wilde J. Bussink J.A. Raleigh A.J. van der Kogel Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer Cancer Res. 62 2002 7066 7074
43. S.J. Kim H.J. Shin K.Y. Jung S.K. Baek B.K. Shin J. Choi B.S. Kim S.W. Shin Y.H. Kim J.S. Kim Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue Jpn. J. Clin. Oncol. 37 2007 812 819
44. M.A. Konerding A.J. Miodonski A. Lametschwandtner Microvascular corrosion casting in the study of tumor vascularity: a review Scanning Microsc. 9 1995 1233 1244
45. M.I. Koukourakis S.M. Bentzen A. Giatromanolaki G.D. Wilson F.M. Daley M.I. Saunders S. Dische E. Sivridis A.L. Harris Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial J. Clin. Oncol. 24 2006 727 735
46. C. Koumenis B.G. Wouters “Translating” tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways Mol. Cancer Res. 4 2006 423 436
47. H.C. Kwaan J. Wang K. Svoboda P.J. Declerck Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis Br. J. Cancer 82 2000 1702 1708
48. Q.T. Le C. Kong P.W. Lavori K. O'Byrne J.T. Erler X. Huang Y. Chen H. Cao R. Tibshirani N. Denko Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas Int. J. Radiat. Oncol. Biol. Phys. 69 2007 167 175
49. Q.T. Le P.D. Sutphin S. Raychaudhuri S.C. Yu D.J. Terris H.S. Lin B. Lum H.A. Pinto A.C. Koong A.J. Giaccia Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas Clin. Cancer Res. 9 2003 59 67
50. A.S. Lee GRP78 induction in cancer: therapeutic and prognostic implications Cancer Res. 67 2007 3496 3499
51. J. Lee D.W. Siemann C.J. Koch E.M. Lord Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts Int. J. Cancer 67 1996 372 378
52. M.P. Look W.L. van-Putten M.J. Duffy N. Harbeck I.J. Christensen C. Thomssen R. Kates F. Spyratos M. Ferno S. Eppenberger-Castori Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients J. Natl. Cancer Inst. 94 2002 116 128
53. M.L. Macheda S. Rogers J.D. Best Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer J. Cell Physiol. 202 2005 654 662
54. N.E. Matthews M.A. Adams L.R. Maxwell T.E. Gofton C.H. Graham Nitric oxide-mediated regulation of chemosensitivity in cancer cells J. Natl. Cancer Inst. 93 2001 1879 1885
55. A. Mayer M. Hockel P. Vaupel Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix Clin. Cancer Res. 11 2005 7220 7225
56. A. Mayer M. Hockel A. Wree P. Vaupel Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers Clin. Cancer Res. 11 2005 2768 2773
57. A. Mayer A. Wree M. Hockel C. Leo H. Pilch P. Vaupel Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix Cancer Res. 64 2004 5876 5881
58. Y. Mizukami Y. Kohgo D.C. Chung Hypoxia inducible factor-1 independent pathways in tumor angiogenesis Clin. Cancer Res. 13 2007 5670 5674
59. E.J. Moon D.M. Brizel J.T. Chi M.W. Dewhirst The potential role of intrinsic hypoxia markers as prognostic variables in cancer Antioxid. Redox. Signal. 9 2007 1237 1294
60. P.E. Morgan S. Pastorekova A.K. Stuart-Tilley S.L. Alper J.R. Casey Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters Am. J. Physiol. Cell Physiol. 293 2007 738 748
61. J.C. Mottram A factor of importance in the radiosensitivity of tumours Br. J. Radiol. IX 1936 606 614
62. M. Nordsmark J. Alsner J. Keller O.S. Nielsen O.M. Jensen M.R. Horsman J. Overgaard Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations Br. J. Cancer 84 2001 1070 1075
63. M. Nordsmark S.M. Bentzen V. Rudat D. Brizel E. Lartigau P. Stadler A. Becker M. Adam M. Molls J. Dunst Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study Radiother. Oncol. 77 2005 18 24
64. M. Nordsmark J. Loncaster C. Aquino-Parsons S.C. Chou V. Gebski C. West J.C. Lindegaard H. Havsteen S.E. Davidson R. Hunter The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study Radiother. Oncol. 80 2006 123 131
65. M. Nozue I. Lee F. Yuan B.A. Teicher D.M. Brizel M.W. Dewhirst C.G. Milross L. Milas C.W. Song C.D. Thomas Interlaboratory variation in oxygen tension measurement by Eppendorf “Histograph” and comparison with hypoxic marker J. Surg. Oncol. 66 1997 30 38
66. R.J. Oliver R.T. Woodwards P. Sloan N.S. Thakker I.J. Stratford R.E. Airley Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies Eur. J. Cancer 40 2004 503 507
67. J. Overgaard J.G. Eriksen M. Nordsmark J. Alsner M.R. Horsman Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial Lancet Oncol. 6 2005 757 764
68. J. Overgaard H.S. Hansen M. Overgaard L. Bastholt A. Berthelsen L. Specht B. Lindelov K. Jorgensen A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 Radiother. Oncol. 46 1998 135 146
69. J. von Pawel R. von-Roemeling U. Gatzemeier M. Boyer L.O. Elisson P. Clark D. Talbot A. Rey T.W. Butler V. Hirsh Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors J. Clin. Oncol. 18 2000 1351 1359
70. A.R. Padhani K.A. Krohn J.S. Lewis M. Alber Imaging oxygenation of human tumours Eur. Radiol. 17 2007 861 872
71. V. Palit R.M. Phillips R. Puri T. Shah M.C. Bibby Expression of HIF-1alpha and Glut-1 in human bladder cancer Oncol. Rep. 14 2005 909 913
72. D.M. Patterson G.J. Rustin Vascular damaging agents Clin. Oncol. 19 2007 443 456
73. I. Petersen Antiangiogenesis, anti-VEGF(R) and outlook Recent Results Cancer Res. 176 2007 189 199
74. N. Pore S. Liu H.K. Shu B. Li D. Haas-Kogan D. Stokoe J. Milanini-Mongiat G. Pages D.M. O'Rourke E. Bernhard Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism Mol. Biol. Cell 15 2004 4841 4853
75. C.P. Potter A.L. Harris Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer Br. J. Cancer 89 2003 2 7
76. J.G. Rajendran D.L. Schwartz J. O'Sullivan L.M. Peterson P. Ng J. Scharnhorst J.R. Grierson K.A. Krohn Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer Clin. Cancer Res. 12 2006 5435 5441
77. J.A. Raleigh S.C. Chou G.E. Arteel M.R. Horsman Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors Radiat. Res. 151 1999 580 589
78. A. Ramankulov M. Lein G. Kristiansen H.A. Meyer S.A. Loening K. Jung Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma J. Cancer Res. Clin. 133 2007 643 652
79. H. Rangaswami A. Bulbule G.C. Kundu Osteopontin: role in cell signaling and cancer progression Trends Cell Biol. 16 2006 79 87
80. M. Rijpkema J.H. Kaanders F.B. Joosten A.J. van der Kogel A. Heerschap Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging Int. J. Radiat. Oncol. Biol. Phys. 53 2002 1185 1191
81. D. Rischin L. Peters R. Fisher A. Macann J. Denham M. Poulsen M. Jackson L. Kenny M. Penniment J. Corry Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02) J. Clin. Oncol. 23 2005 79 87
82. S.R. Rittling A.F. Chambers Role of osteopontin in tumour progression Br. J. Cancer 90 2004 1877 1881
83. S. Rogers M.L. Macheda S.E. Docherty M.D. Carty M.A. Henderson W.C. Soeller E.M. Gibbs D.E. James J.D. Best Identification of a novel glucose transporter-like protein-GLUT-12 Am. J. Physiol. Endocrinol. Metab. 282 2002 E733 E738
84. P.S. Rudland A. Platt-Higgins M. El-Tanani S. De-Silva-Rudland R. Barraclough J.H. Winstanley R. Howitt C.R. West Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer Cancer Res. 62 2002 3417 3427
85. A. Sandler R. Gray M.C. Perry J. Brahmer J.H. Schiller A. Dowlati R. Lilenbaum D.H. Johnson Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer New Engl. J. Med. 355 2006 2542 2550
86. D. Schilling C. Bayer A. Geurts-Moespot F.C. Sweep M. Pruschy K. Mengele L.D. Sprague M. Molls Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines BMC Cancer 7 2007 143
87. J. Schuuring J. Bussink H.J. Bernsen W. Peeters A.J. van-Der-Kogel Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line Int. J. Radiat. Oncol. Biol. Phys. 61 2005 529 534
88. G.L. Semenza Hypoxia, clonal selection, and the role of HIF-1 in tumor progression Crit. Rev. Biochem. Mol. Biol. 35 2000 71 103
89. G.L. Semenza Evaluation of HIF-1 inhibitors as anticancer agents Drug Discov. Today 12 2007 853 859
90. P.N. Span J. Bussink P. Manders L.V. Beex C.G. Sweep Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome Br. J. Cancer 89 2003 271 276
91. A.B. Stillebroer E. Oosterwijk W.J. Oyen P.F. Mulders O.C. Boerman Radiolabeled antibodies in renal cell carcinoma Cancer Imaging 7 2007 179 188 The official publication of the International Cancer Imaging Society
92. D.C. Talbot J. von Pawel E. Cattell S.M. Yule C. Johnston A.S. Zandvliet A.D. Huitema C.J. Norbury P. Ellis L. Bosquee A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer Clin. Cancer Res. 13 2007 1816 1822
93. O. Tredan C.M. Galmarini K. Patel I.F. Tannock Drug resistance and the solid tumor microenvironment J. Natl. Cancer Inst. 99 2007 1441 1454
94. E.G. Troost J. Bussink J.H. Kaanders J. van-Eerd J.P. Peters P.F. Rijken O.C. Boerman A.J. van-der-Kogel Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines Radiother. Oncol. 76 2005 194 199
95. P. Vaupel O. Thews M. Hoeckel Treatment resistance of solid tumors: role of hypoxia and anemia Med. Oncol 18 2001 243 259
96. G.L. Wang B.H. Jiang E.A. Rue G.L. Semenza Hypoxia-inducible factor 1 is a basic-helix-loop–helix-PAS heterodimer regulated by cellular O2 tension Proc. Natl. Acad. Sci. USA 92 1995 5510 5514
97. S.K. Williamson J.J. Crowley P.N. Lara Jr. J. McCoy D.H. Lau R.W. Tucker G.M. Mills D.R. Gandara Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003 J. Clin. Oncol. 23 2005 9097 9104
98. R.E. Wilson P.C. Keng R.M. Sutherland Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia J. Natl. Cancer Inst 81 1989 1235 1240
99. B.G. Wouters J.M. Brown Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiotherapy Radiat. Res. 147 1997 541 550
100. C.C. Wykoff N.J.P. Beasley P.H. Watson K.J. Turner J. Pastorek A. Sibtain G.D. Wilson H. Turley K.L. Talks P.H. Maxwell Hypoxia-inducible expression of tumor-associated carbonic anhydrases Cancer Res. 60 2000 7075 7083
101. H. Zhang Q.H. Ye N. Ren L. Zhao Y.F. Wang X. Wu H.C. Sun L. Wang B.H. Zhang Y.K. Liu The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma J. Cancer Res. Clin. 132 2006 709 717
102. H. Zhong A.M. De-Marzo E. Laughner M. Lim D.A. Hilton D. Zagzag P. Buechler W.B. Isaacs G.L. Semenza J.W. Simons Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases Cancer Res. 59 1999 5830 5835